This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.
No linked publications found in PubMed
Inclusion Criteria: * confirmed intrahepatic cholangiocarcinoma * with Resectable tumor lesion * no contraindications to surgery * with high risk of tumour recurrence * No prior systemic therapy for intrahepatic cholangiocarcinoma. * ECOG Performance Status of 0 or 1 * Child-Pugh Class: Grade A Exclusion Criteria: * History of gastrointestinal hemorrhage within 6 months prior to the start of study treatment or clear tendency of gastrointestinal hemorrhage * Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess within 6 months prior to the start of study treatment * Known genetic or acquired hemorrhage or thrombotic tendency * Thrombosis or thromboembolic event within 6 months prior to the start of study treatment * Cardiac clinical symptom or disease that is not well controlled * Hypertension that can not be well controlled through antihypertensive drugs